Nerkardou (5 mg) & (10 mg) — Competitive Intelligence Brief

Nerkardou (5 mg) & (10 mg) (Nerkardou (5 mg) & (10 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID). Area: Rheumatology.

marketed Nonsteroidal anti-inflammatory drug (NSAID) COX-2 Rheumatology Small molecule

Target snapshot

Nerkardou (5 mg) & (10 mg) (Nerkardou (5 mg) & (10 mg)) — Genuine Research Center, Egypt. Nerkardou is an anti-inflammatory agent that works by inhibiting the production of pro-inflammatory cytokines.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Nerkardou (5 mg) & (10 mg) TARGET	Nerkardou (5 mg) & (10 mg)	Genuine Research Center, Egypt	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-2
Celebrex	celecoxib	Pfizer Inc. (originally Searle/Pharmacia)	marketed	Nonsteroidal Anti-inflammatory Drug [EPC]	COX-2	1998-12-31
Cytotec	Misoprostol	Pfizer	marketed	NSAID combined with prostaglandin analog	Cyclooxygenase (COX-1 and COX-2); Prostaglandin receptors	1988-01-01
NSAID (Ketorolac/Ibuprofen)	NSAID (Ketorolac/Ibuprofen)	Thomas Jefferson University	marketed	Non-steroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
morphine ,ketorolac	morphine ,ketorolac	Jose Antonio Bernia Gil	marketed	Opioid analgesic + NSAID combination	Opioid receptors (μ, δ, κ); COX-1 and COX-2 enzymes
Morphine, Parecoxib	Morphine, Parecoxib	Pfizer	marketed	Opioid analgesic combined with selective COX-2 inhibitor	Mu-opioid receptor (morphine); COX-2 enzyme (parecoxib)
Motrin/Percocet/Dilaudid for breakthrough	Motrin/Percocet/Dilaudid for breakthrough	University Hospitals Cleveland Medical Center	marketed	Combination analgesic regimen (NSAID + opioid + potent opioid)	Cyclooxygenase (COX-1/COX-2); mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2036-05-27 — Celebrex · 10722456 · Formulation · US
• 2036-05-27 — Celebrex · 10799517 · Formulation · US
• 2036-05-27 — Celebrex · 9949990 · Formulation · US
• 2036-05-27 — Celebrex · 9795620 · Formulation · US
• 2036-05-27 — Celebrex · 9572819 · Formulation · US
• 2036-05-27 — Celebrex · 10376527 · Formulation · US

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID) class)

1. Università degli Studi di Brescia · 4 drugs in this class
2. Bausch & Lomb Incorporated · 4 drugs in this class
3. Bayer · 3 drugs in this class
4. Pfizer · 3 drugs in this class
5. Azienda USL Reggio Emilia - IRCCS · 3 drugs in this class
6. Organon and Co · 3 drugs in this class
7. Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division · 2 drugs in this class
8. Bezmialem Vakif University · 2 drugs in this class
9. Guang'anmen Hospital of China Academy of Chinese Medical Sciences · 2 drugs in this class
10. Center For Excellence In Eye Care · 2 drugs in this class